The clinical effectiveness, safety, and pharmacological profile of ION363 (jacifusen) are currently under scrutiny in a Phase III clinical trial started from 2021 by Ionis, involving ALS patients with FUS mutations (FUSION; NCT04768972). This evidence concerns the gene FUS and amyotrophic lateral sclerosis.